If you qualify for the study, you will be placed by chance in a treatment group to receive one of two doses of brepocitinib or placebo.
Investigational medicine means that it has not been approved by country-specific regulatory health authorities to be used for dermatomyositis and its use is being allowed for research purposes only.
The placebo looks like brepocitinib but contains no active medicine. This gives researchers something to compare the study drug to in order to better understand its effects.
You will continue to receive your current medication in addition to the study drug. The study doctor will advise you on which medication(s) you will continue to take.
A computer is used to assign study participants to study treatment groups by chance, like flipping a coin. This is called randomization.
Like all medicines, there is a chance for side effects, which are unwanted and unintended effects from a medicine. Your health will be closely monitored during the entire study. It is very important to tell the study doctor if you notice any changes in your health or if anything is bothering you.
For more information about dermatomyositis, including access to support and resources, please visit the links below.
For those in the US:
International resources: